MARKET OPPORTUNITY INOVIQ is an integrated diagnostics and therapeutics company developing exosome-based products for earlier detection and targeted treatment of cancer. INOVIQ’s core exosome technology isolates extracellular vesicles (EVs) with high specificity and purity, unlocking high value applications across diagnostics for minimally-invasive early cancer detection and therapeutics for targeted, cell free treatments for solid tumours. Exosome Technology and Applications Exosomes (or small extracellular vesicles, sEVs) are released by all cells and perform key roles in intercellular communication, immune regulation and disease progression. They carry molecular cargo including DNA, RNAs, proteins and lipids that act as biomarkers of disease or cell messengers. INOVIQ is positioned to capitalise on the significant commercial potential of exosomes for research, diagnosis and treatment of cancer, cardiovascular, inflammatory, neurodegenerative, and other diseases. The global exosome market is forecast to grow rapidly over the next decade, driven by increasing adoption of non-invasive molecular diagnostics, liquid biopsy technologies and exosome-based therapeutics. Reports have predicted the global exosome market to reach between US$1.2 to $6.8 billion by 2032-33, growing at a CAGR of between 23-81.2%1,2. Exosomes offer enhanced diagnostic sensitivity and specificity, while also emerging as highly effective drug delivery vehicles and potential alternatives to complex and costly cell therapies. A key constraint on broader industry adoption remains the lack of scalable, clinically and commercially viable exosome isolation and manufacturing technologies. INOVIQ’s proprietary platform is designed to address these challenges, unlocking the potential of exosomes for biomarker discovery, diagnostics and therapeutics. The Company has already commercialised its EXONET® exosome isolation technology through global partner Promega, is advancing ovarian cancer screening diagnostics, and progressing preclinical exosome therapeutics for solid tumours. Cancer Diagnostics Opportunity EXO-OC™ is INOVIQ’s lead product in development for early detection of ovarian cancer. Ovarian cancer is the world’s deadliest gynaecological cancer with 330,000 cases and 207,000 deaths worldwide3, and a global diagnostic market expected to reach US$3.1 billion by 20354. Ovarian cancer is typically diagnosed at a late stage, resulting in poor survival outcomes despite available treatments. Early detection represents the greatest opportunity to improve patient outcomes and reduce healthcare burden. EXO-OC™ addresses a critical unmet need for early detection of ovarian cancer. INOVIQ’s strategy is to first commercialise EXO-OC™ as a Laboratory Developed Test (LDT) in the US for early detection of ovarian cancer in high-risk women, and then further develop the test as an In Vitro Diagnostic (IVD) for ovarian cancer screening in average-risk women. Cancer Therapeutics Opportunity INOVIQ is developing chimeric antigen receptor (CAR)- exosomes, a next-generation cell-free therapy derived from modified immune cells to target and kill solid tumours. CAR-exosomes inherit the tumour-targeting and cytotoxic capabilities of their parent cells with potential manufacturing, safety and efficacy advantages over autologous cell therapies. INOVIQ is shaping the future of cancer care, targeting aggressive solid tumours with our off-the-shelf cell-free therapeutic platform. Our lead candidate is an Epidermal Growth Factor Receptor (EGFR)-targeted CAR-exosome therapy in preclinical development for triple-negative breast cancer (TNBC). The breast cancer market is anticipated to reach US$28 billion by 2032 in the US alone5. TNBC the deadliest and most aggressive subtype of breast cancer, representing 10-15% of all breast cancer cases6 with up to 40% of TNBC cancers recurring within 5 years7. TNBC lacks common therapeutic targets (ER, PR, HER22) and has limited treatment options, high recurrence and poor prognosis. INOVIQ’s EGFR-CAR-NK-EVs aim to deliver targeted cancer-killing activity against EGFR-expressing TNBC and other solid tumours to improve treatment outcomes and survival. INOVIQ’s CAR-exosome pipeline includes an ovarian cancer therapeutic. Ovarian cancer remains a major global health challenge, with more than 330,000 women diagnosed worldwide each year8. It is the deadliest gynaecological cancer with only 47% survival 5 years post-diagnosis9. The global ovarian cancer therapeutics market is expected to reach US$6.65 billion in 202610. Like TNBC, ovarian cancer is often aggressive and difficult to treat, particularly as most patients are diagnosed at a late stage when treatment options are limited. Current standard of care typically involves cytoreductive surgery followed by platinum-based chemotherapy, with selected patients receiving maintenance or targeted therapies. However, high rates of recurrence and treatment resistance continue to drive the need for new therapeutic approaches. 1 Grand View Research 2026, Exosomes Market (2026-2033) 2 Markets and Markets 2024, Exosome Diagnostics and therapeutics Market - Global Forecast to 2032 3 Global Cancer Observatory, Cancer Today - Ovary Factsheet 4 Grand View Research 2025, Ovarian Cancer Diagnostics Market, 2025-2033 5 Oncology’s Next Decade: The Therapies and Players Reshaping a $400bm Future, Evaluate, July 2026 6 NCI SEER, Female Breast Cancer Subtypes 7 WebMD, Triple-Negative Breast Cancer, February 20 2024 8 Global Cancer Observatory, Cancer Today - Ovary Factsheet 9 Lheureux et al, CA: A Cancer Journal for Clinicians, 17 May 2019 10 Research and Markets, Ovarian Cancer Drugs Market Report 2026 6 INOVIQ Limited Review of Operations continued
RkJQdWJsaXNoZXIy MjE2NDg3